Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.
AffiliationDepartamento de Oncología Médica, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041, Madrid, Spain
MetadataShow full item record
AbstractNeuroendocrine tumors (NETs) are rare tumors that have been increasing in incidence over the last 30 years with no significant changes in survival. As survival of patients with these tumors depends greatly on stage and histology, early diagnosis, classification and staging of tumors in patients in whom NETs are suspected are of great importance. Surgery, either with curative or palliative intent, is the mainstay of treatment for localized NETs. Therapeutic options for this disease almost invariably include somatostatin analogs to alleviate the symptoms of excessive hormone secretion. Other approaches for advanced disease may include hepatic artery embolization or ablation, peptide receptor radionuclide therapy and systemic chemotherapy. Recent advances regarding the signaling pathways involved in tumor development have allowed the development of novel targeted therapies. However, due to the lack of prognostic molecular markers to identify high-risk patients and the absence of a common pathogenesis in all patients, treatment selection is often empirical. There is therefore a need to establish a consensus for the treatment of this disease and to provide evidence-based clinical recommendations and algorithms to optimize and individualize the treatment and follow-up for these patients.
CitationExpert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. 2015, 75 (6):1099-114 Cancer Chemother Pharmacol
JournalCancer Chemotherapy and Pharmacology
- Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
- Authors: Ganetsky A, Bhatt V
- Issue date: 2012 Jun
- Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
- Authors: Desai KK, Khan MS, Toumpanakis C, Caplin ME
- Issue date: 2009 Dec
- Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
- Authors: Chan JA, Kulke MH
- Issue date: 2016 Apr
- A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.
- Authors: Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke MH
- Issue date: 2013 Jun
- New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
- Authors: Lawrence B, Gustafsson BI, Kidd M, Modlin I
- Issue date: 2010 Sep